Inactive Instrument

Genomic Health, Inc.

Equities

US37244C1018

Biotechnology & Medical Research

Genomic Health, Inc. Elects Henry J. Fuchs as Member of the Board of Directors

September 20, 2013 at 06:02 am EDT

On September 17, 2013, the Board of Directors of Genomic Health Inc. elected Henry J. Fuchs, M.D., a member of the Board of Directors of the company. Since March 2009, Dr. Fuchs has served as the Executive Vice President and Chief Medical Officer of BioMarin Pharmaceutical Inc. From September 2005 to December 2008, Dr. Fuchs was Executive Vice President and Chief Medical Officer of Onyx Pharmaceuticals Inc.

Latest news about Genomic Health, Inc.

MDxHealth SA acquired Oncotype DX GPS Prostate Cancer Business from Genomic Health, Inc. for approximately $100 million.	22-08-01	CI
Biocartis Group NV and Biocartis and Genomic Health, Inc. Agree to End Collaboration Due to Changed Market Circumstances	20-10-29	CI
Genomic Health, Inc. Announces Executive Changes	19-11-08	CI
Genomic Health, Inc.(NasdaqGS:GHDX) dropped from S&P 1000	19-11-08	CI
Genomic Health, Inc.(NasdaqGS:GHDX) dropped from S&P 600 Health Care	19-11-08	CI
Genomic Health, Inc.(NasdaqGS:GHDX) dropped from S&P 600	19-11-08	CI
Genomic Health, Inc.(NasdaqGS:GHDX) dropped from S&P Global BMI Index	19-11-08	CI
Genomic Health, Inc.(NasdaqGS:GHDX) dropped from S&P Composite 1500	19-11-08	CI
Genomic Health, Inc.(NasdaqGS:GHDX) dropped from S&P TMI Index	19-11-08	CI
Genomic Health, Inc.(NasdaqGS:GHDX) dropped from S&P Biotechnology Select Industry Index	19-11-08	CI
Genomic Health, Inc.(NasdaqGM:GHDX) dropped from NASDAQ Composite Index	19-11-08	CI
Exact Sciences Corporation completed the acquisition of Exact Sciences Corporation from Baker Bros. Advisors LP and others.	19-11-07	CI
Genomic Health, Inc.(NasdaqGS:GHDX) dropped from NASDAQ Biotechnology Index	19-11-07	CI
Genomic Health Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-10-30	CI
Genomic Health, Inc. Announces Results from a New Analysis of the Trial Assigning IndividuaLised Options for Treatment (Rx), or TAILORx	19-09-30	CI
New St. Gallen International Breast Cancer Guidelines Recommends Oncotype DX Breast Recurrence Score® Test to Guide Chemotherapy for Node-negative and Node-positive Early-stage Breast Cancer	19-08-21	CI
EXACT Sciences : Diagnostic company Exact Sciences to buy Genomic Health in $2.8 billion deal	19-07-29	RE
GLOBAL MARKETS LIVE: Sprint, T-Mobile, Refinitiv, Pfizer…	19-07-29
Genomic Health, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-07-29	CI
Genomic Health, Inc. Revised Earnings Guidance for the Full Year of 2019	19-07-29	CI
Genomic Health, Inc.(NasdaqGS:GHDX) added to S&P 600 Health Care	19-07-29	CI
Genomic Health, Inc.(NasdaqGS:GHDX) added to S&P Composite 1500	19-07-29	CI
Genomic Health, Inc.(NasdaqGS:GHDX) added to S&P 600	19-07-29	CI
Genomic Health, Inc.(NasdaqGS:GHDX) added to S&P 1000	19-07-29	CI
Exact Sciences Corporation signed a definitive agreement to acquire Genomic Health, Inc. from Baker Bros. Advisors LP and others for $2.8 billion.	19-07-28	CI

Chart Genomic Health, Inc.

Duration

Period

More charts

Company Profile

Genomic Health, Inc. is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company's Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test. Its research and development activities are focused on developing a pipeline of tests to optimize the treatment of various cancers including breast, colon, prostate and other cancers. It offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS), and a Genomic Prostate Score, for prostate cancer.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+33.63%	50.93B
IQVIA HOLDINGS INC.	-0.09%	42.12B
LONZA GROUP AG	+49.62%	42.05B
CELLTRION, INC.	-4.96%	29.18B
ICON PUBLIC LIMITED COMPANY	+11.18%	26.02B
ALNYLAM PHARMACEUTICALS, INC.	-21.95%	18.9B
BIO-TECHNE CORPORATION	+8.61%	13.21B
UNITED THERAPEUTICS CORPORATION	+24.73%	12.17B
MEDPACE HOLDINGS, INC.	+28.31%	12.16B

Other Biotechnology & Medical Research